Sepracor and Nycomed : exclusive development, marketing and commercialization agreement for ciclesonide in the U.S.

Jan. 28, 2008--Sepracor Inc. (Nasdaq: SEPR) and Nycomed announced an exclusive development, marketing and commercialization agreement for ciclesonide in the United States. Ciclesonide, Nycomed's proprietary corticosteroid, has a unique activation mechanism and is the active ingredient in ALVESCO HFA (hydrofluoroalkane) Inhalation Aerosol MDI (metered-dose inhaler) for the treatment of asthma and in OMNARIS AQ Nasal Spray for the treatment of allergic rhinitis. The broad ciclesonide franchise complements Sepracor's respiratory portfolio and further leverages the company's commercial infrastructure with both OMNARIS AQ and ALVESCO HFA projected to be launched in 2008... Sepracor's Press Release - Nycomed's Press Release-